Pluviaendo Visuals Pluviaendo Visuals

X
[{"orgOrder":0,"company":"Planet Biotechnology","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Planet Biotechnology

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the terms of the agreement, iBio obtained an exclusive license to Planet’s ACE2-Fc. Planet is eligible to receive certain pre-specified payments upon achievement of clinical development milestones.

            Lead Product(s): ACE2-Fc

            Therapeutic Area: Infections and Infectious Diseases Product Name: ACE2-Fc

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: iBio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 28, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY